GlassScriptPhysician profile
George Shokri
NPI 1851677074
$22,224.02
in general payments reported to CMS, 2019-2025
47 companies · $2,285 in 2025
The $2,285 reported for 2025 was more than what 75% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,735 · 2020: $519 · 2021: $1,527 · 2022: $5,159 · 2023: $7,939 · 2024: $3,060 · 2025: $2,285.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,481 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,781 · Education: $21.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,480.98 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,781.25 |
| Education | $21.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $6,734.07 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Biohaven Pharmaceutical Holding Company LTD. | $2,821.21 | 2022 | |
| Ucb, INC. | $1,454.47 | 2019-2025 | Briviact, Nayzilam, Rystiggo |
| Biogen, INC. | $1,384.87 | 2019-2025 | Vumerity, Tysabri, Skyclarys |
| Sk Life Science, INC. | $1,226.24 | 2020-2025 | |
| Pfizer INC. | $776.49 | 2019-2025 | |
| Lilly USA, LLC | $743.51 | 2019-2025 | Emgality, Kisunla, Amyvid |
| Celgene Corporation | $641.03 | 2021-2024 | Zeposia |
| Novartis Pharmaceuticals Corporation | $621.00 | 2019-2025 | |
| Eisai INC. | $585.01 | 2019-2025 | |
| Amgen INC. | $544.03 | 2019-2023 | Aimovig |
| Lundbeck LLC | $517.96 | 2022-2025 | Vyepti |
| Neurocrine Biosciences, INC. | $377.68 | 2022-2025 | Ingrezza, Ongentys |
| Teva Pharmaceuticals USA, INC. | $377.48 | 2019-2024 | Austedo Xr, Austedo |
| Alexion Pharmaceuticals, INC. | $301.45 | 2019-2022 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Shokri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.